Table 1

Baseline characteristics of RA subjects at cohort entry (n=16 207)

Age (years, mean (SD))70.9 (5.9)
Female (number (%))68.3
DMARD use at cohort entry*
 Anti-TNF therapy0.01
 Others (ciclosporin, mycophenolate mofetil, d-penicillamine)2.8
  • * Patients could receive combination disease-modifying antirheumatic drug (DMARD) therapy and contribute to more than one drug category, allowing total to exceed 100%.

  • RA, rheumatoid arthritis; TNF, tumour necrosis factor.